I was looking at some research on curcumin from UCLA and Alzheimer’s study. The research showed 80 milligrams to 135 milligrams for prevention and citing India’s intake. It points up to eight capsules of Longvida, which I think is about 800 milligrams of curcumin for therapeutic purposes. I don’t think we’ve gone into this, but what’s your approach for finding the right dose? A lot of practitioners have spoken about curcumin not being beneficial. Do you think it could be a case of not high enough dose? Same goes for boswellia, and I’ve seen studies showing 600 and 900 milligrams.

Chris Kresser:  Yeah, I do think it’s a question of dose and I provided a starting dose there when we talked about Longvida, and I think we even talked about often having patients start with a higher dose and then titrate down. That can sometimes be helpful. But it’s certainly possible that we’re not using high enough doses. I mean the intake, India’s intake, that’s coming from food-based form that’s not well-absorbed. So I don’t know how applicable that is to comparing that to Longvida milligram by milligram. But certainly if your patient doesn’t respond to curcumin, you could try upping the dose. I would just be, it’s not clear how long a dose that high would be safe for. There’s been studies on lower doses of curcumin standing out to two years, but not for these higher doses. So that’s something to consider.